Staying on 5mg Mounjaro: what your prescriber is actually watching for

5mg is the first active therapeutic dose of tirzepatide — the 2.5mg starting pen is a tolerability step, not a treatment level in its own right.
Dose increases are not automatic; your prescriber considers how much weight you've lost, how well you're tolerating the current dose, and your wider health picture before recommending a change.
Staying at 5mg is a legitimate clinical choice, some people lose meaningful weight here and experience fewer side effects than at higher doses.
Moving up is not the only measure of progress; if 5mg is working and you're comfortable, there is often no clinical reason to push higher.

You've finished your 2.5mg starter pen and moved to 5mg — and now the question sitting in your head is whether staying on 5mg Mounjaro longer is a reasonable choice or a sign something isn't working. The short answer: for many people, 5mg is a productive, well-tolerated dose worth holding for longer than the standard four-week window, and the decision belongs with your prescriber, not with a dose-escalation timetable. These are prescription-only medicines, and any change to your dose should follow a clinical review rather than a schedule you set yourself.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The clinical thinking behind holding or moving past 5mg, and how to have that conversation

Picture this: four weeks in, the pen is working, but you're not sure whether to push for more

You've been on 5mg for a month. Nausea has settled. Your appetite is noticeably smaller. The scale has moved, not dramatically, but in the right direction. And your next prescription review is coming up. A common misconception at this point is that staying put means the treatment isn't working hard enough. It doesn't. Tirzepatide's dose escalation exists partly to manage tolerability, not solely to chase faster results. Some people reach a weight-loss rate at 5mg that their prescriber is entirely satisfied with, and holding there for another four weeks (or longer) is a sound clinical call.

The full picture of how Mounjaro works helps here: as a dual GIP and GLP-1 receptor agonist, tirzepatide reduces appetite and slows gastric emptying. Both effects are present at 5mg. Higher doses tend to amplify them, but that also means more pronounced side effects for some people. If you are tolerating 5mg well and losing weight steadily, your prescriber has good reason to take stock before recommending 7.5mg.

The NHS tirzepatide information page confirms that doses are increased gradually, and that the prescriber leads the timing of each step based on individual response.

What your prescriber is measuring, and what 'not enough progress' actually means

Prescribers typically look at weight change over a defined period when deciding whether your current dose is doing its job. NICE's guidance on tirzepatide (TA1026) notes that continuing treatment should be reviewed if weight loss falls below 5% after six months at the highest tolerated dose, but 5mg is rarely the highest tolerated dose, and six months is the long-game benchmark, not the four-week one.

In practice, your prescriber is weighing several things at once: how much weight you've lost since starting, whether side effects are manageable, how close you are to your health goals, and whether your body seems to be responding or has plateaued. The decision about whether to stay on 5mg is therefore personal, and not one that a standard schedule can make for you.

If you genuinely feel ready to move up, say so. If you'd rather hold at a dose that's working without pushing your system further, that's worth saying too. Prescribers are not trying to rush you through the dose ladder. They want the best outcome at the lowest burden to you.

For anyone considering the financial side of longer periods at the same dose, our treatment and cost information gives an honest picture of what a private prescription includes.

Side effects, tolerance, and the case for not rushing past 5mg

A small but real group of people find that moving to 7.5mg brings a return of nausea, vomiting or stomach cramps they thought they'd left behind. If 5mg is genuinely comfortable and effective, that comfort has clinical value. The 5mg dose is where most people first feel the appetite-suppressing effect clearly, and staying on 5mg Mounjaro while your body adapts is a legitimate strategy, not a failure to progress.

The side-effect profile at any dose is dominated by gastrointestinal effects: nausea, loose stools, constipation, indigestion, and sometimes burping or fatigue. These are most noticeable after starting or stepping up, and often ease within one to two weeks. If you're still managing significant side effects four weeks into 5mg, your prescriber needs to know before any upward move is considered. Pushing the dose while you're still symptomatic is not the right call.

If you started your journey at 2.5mg and are thinking about how that lower starting dose compares, staying on the 2.5mg starter dose is covered separately, the dynamics are different because 2.5mg is a tolerability step rather than an active treatment tier.

How long is reasonable, and when to revisit the question

There is no single correct answer to how long someone should stay on 5mg. Some clinical pathways move people on after four weeks as standard; others extend to eight or twelve weeks if the response is good and the person prefers to hold. How long to stay on 5mg is worth reading if timing is your main question, it covers what evidence and clinical practice suggest.

What matters is that the review actually happens. At nume, a real prescriber reads your update at every repeat, including evidence of your current weight and any changes since the last pen. No automated escalation, no box-ticking. If you want to discuss whether staying put is right for you, or whether there's a clinical reason to move to the 10mg range further down the line, that conversation is part of the service.

Explore all weight-loss treatment options or speak to our prescribers if you'd like a clinical view on where you are in your treatment.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions